{"id":109,"date":"2013-01-29T10:29:18","date_gmt":"2013-01-29T09:29:18","guid":{"rendered":"http:\/\/surmedicalisation.fr\/?page_id=109"},"modified":"2014-01-28T13:09:19","modified_gmt":"2014-01-28T12:09:19","slug":"revue-de-presse","status":"publish","type":"page","link":"http:\/\/surmedicalisation.fr\/?page_id=109","title":{"rendered":"Revue de presse"},"content":{"rendered":"<p><script type=\"text\/javascript\">\/\/ <![CDATA[\n(function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){   (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),   m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)   })(window,document,'script','\/\/www.google-analytics.com\/analytics.js','ga');   ga('create', 'UA-40453293-1', 'surmedicalisation.fr');   ga('send', 'pageview');\n\/\/ ]]><\/script><\/p>\n<h1 itemprop=\"Headline\"><\/h1>\n<p><strong>08\/05\/2013 En Belgique, le cas d&rsquo;un enfant atteint d&rsquo;une maladie rare suscite la pol\u00e9mique Jean-Pierre Stroobants Le Monde<\/strong><\/p>\n<p>Un petit gar\u00e7on de 7 ans, Viktor Ameys, pourra continuer \u00e0 vivre gr\u00e2ce \u00e0 un m\u00e9dicament tr\u00e8s co\u00fbteux susceptible de soigner la maladie rare dont il souffre. Depuis plusieurs jours, le cas de l&rsquo;enfant avait suscit\u00e9 beaucoup d&rsquo;attention en Belgique parce qu&rsquo;il posait la question \u00e9thique des limites \u00e9ventuelles du remboursement par la S\u00e9curit\u00e9 sociale \u2013 son traitement co\u00fbte 18 000 euros par mois \u2013 et des choix \u00e0 op\u00e9rer par le monde politique en p\u00e9riode de rigueur. Au fil du temps, l&rsquo;affaire a aussi illustr\u00e9 l&rsquo;attitude de certaines firmes pharmaceutiques : celle qui fabrique le m\u00e9dicament de Viktor n&rsquo;a pas h\u00e9sit\u00e9 \u00e0 m\u00e9diatiser le cas du jeune gar\u00e7on afin d&rsquo;exercer une pression maximale sur la ministre de la sant\u00e9.<\/p>\n<p><span style=\"font-size: medium;\">&#8230;\u00a0<strong>Le dossier est toutefois jug\u00e9 exemplaire pour d&rsquo;autres raisons.\u00a0<em>\u00ab\u00a0En laissant la quasi-totalit\u00e9 de la recherche m\u00e9dicale au secteur priv\u00e9, les gouvernements se sont mis en situation de devoir accepter de<\/em>\u00a0<em>payer le prix demand\u00e9 ou de para\u00eetre refuser un soi<\/em><em>n\u00a0\u00bb,<\/em>\u00a0d\u00e9plore par exemple, dans le journal\u00a0<em>Le Soir<\/em>, Michel Roland, professeur de m\u00e9decine g\u00e9n\u00e9rale \u00e0 l&rsquo;Universit\u00e9 libre de Bruxelles.<\/strong><\/span><\/p>\n<p>La suite sur Le Monde (\u00e9dition abonn\u00e9s)\u00a0<a href=\"http:\/\/abonnes.lemonde.fr\/europe\/article\/2013\/05\/08\/en-belgique-le-cas-d-un-enfant-atteint-d-une-maladie-rare-suscite-la-polemique_3173409_3214.html?xtmc=belgique&amp;xtcr=3\" target=\"_blank\">http:\/\/abonnes.lemonde.fr\/europe\/article\/2013\/05\/08\/en-belgique-le-cas-d-un-enfant-atteint-d-une-maladie-rare-suscite-la-polemique_3173409_3214.html?xtmc=belgique&amp;xtcr=3<\/a><\/p>\n<p>&nbsp;<\/p>\n<p><strong>06\/05\/2013 &#8211; \u00ab Un tr\u00e8s grand nombre d&rsquo;examens sont inutiles \u00bb, selon le Pr Didier Sicard, du Comit\u00e9 national d\u2019\u00e9thique &#8211; Brigitte B\u00e8gue, Journaliste &#8211; VIVA<\/strong><\/p>\n<p>\u00ab\u00a0Sur- et sous-m\u00e9dicalisation, surdiagnostics, surtraitements\u00a0\u00bb, c&rsquo;\u00e9tait le th\u00e8me d&rsquo;un colloque organis\u00e9 les 3 et 4 mai par le groupe Princeps qui rassemble des professionnels de la sant\u00e9, le d\u00e9partement de m\u00e9decine g\u00e9n\u00e9rale de la facult\u00e9 de m\u00e9decine de Bobigny, la Soci\u00e9t\u00e9 de formation \u00e0 la th\u00e9rapeutique du g\u00e9n\u00e9raliste. <a href=\"http:\/\/www.viva.presse.fr\/\/un-tres-grand-nombre-examens-sont-inutiles-selon-le-pr-didier-sicard-du-comite-national-ethique\" target=\"_blank\">Lire la suite sur le site de VIVA\u2026<\/a><\/p>\n<p>&nbsp;<\/p>\n<p>The Globe and Mail 22 f\u00e9vrier 2012\u00a0<strong><a href=\"http:\/\/www.theglobeandmail.com\/arts\/books-and-media\/book-reviews\/ben-goldacre-and-big-pharmas-big-betrayal\/article8964112\/\" target=\"_blank\">Ben Goldacre and big pharma&rsquo;s big betrayal<\/a>\u00a0<\/strong><\/p>\n<p>It takes only three words to sum up the key message of Ben Goldacre\u2019s new book,<em>Bad Pharma<\/em>: Missing data kills.<\/p>\n<p><a href=\"http:\/\/surmedicalisation.fr\/blog\/WordPress3\/wp-content\/uploads\/2013\/01\/Capture-d\u2019\u00e9cran-2013-02-24-\u00e0-19.53.48.png\"><img loading=\"lazy\" class=\"alignnone size-full wp-image-189\" alt=\"Capture d\u2019\u00e9cran 2013-02-24 \u00e0 19.53.48\" src=\"http:\/\/surmedicalisation.fr\/blog\/WordPress3\/wp-content\/uploads\/2013\/01\/Capture-d\u2019\u00e9cran-2013-02-24-\u00e0-19.53.48.png\" width=\"645\" height=\"582\" srcset=\"http:\/\/surmedicalisation.fr\/blog\/WordPress3\/wp-content\/uploads\/2013\/01\/Capture-d\u2019\u00e9cran-2013-02-24-\u00e0-19.53.48.png 645w, http:\/\/surmedicalisation.fr\/blog\/WordPress3\/wp-content\/uploads\/2013\/01\/Capture-d\u2019\u00e9cran-2013-02-24-\u00e0-19.53.48-300x270.png 300w\" sizes=\"(max-width: 645px) 100vw, 645px\" \/><\/a><\/p>\n<p>Consumer Report \u00a0Mars 2013 <a href=\"http:\/\/www.consumerreports.org\/cro\/magazine\/2013\/03\/the-cancer-tests-you-need-and-those-you-don-t\/index.htm\" target=\"_blank\"><strong>The cancer tests you need- and those you don&rsquo;t<\/strong><\/a><\/p>\n<p>As our understanding of cancer changes, doctors and patients are learning that screening tests can sometimes do more harm than good<\/p>\n<p>&#8230;\u201cThe medical and public-health community has systematically exaggerated the benefits of screening for years and downplayed the harms,\u201d says H. Gilbert Welch, M.D., a professor of medicine at the Dartmouth Institute for Health Policy and Clinical Practice in Lebanon, N.H. &#8230;<\/p>\n<p>AFP 22 f\u00e9vrier 2013\u00a0<a href=\"http:\/\/www.google.com\/hostednews\/afp\/article\/ALeqM5hFFBP5CE9gA3EQ1WKdrVH2cv-L7Q?docId=CNG.f810f1dab5bd1233ee632804c2f5dd7e.1f1\" target=\"_blank\">\u00a0<strong>La chirurgie de l&rsquo;ob\u00e9sit\u00e9: un essor qui reste \u00e0 ma\u00eetrise<\/strong><\/a><strong>r<\/strong><\/p>\n<p>&#8230; L&rsquo;\u00e9tude de l&rsquo;Assurance maladie r\u00e9v\u00e8le d&rsquo;importantes disparit\u00e9s r\u00e9gionales avec des taux d&rsquo;intervention qui varie d&rsquo;un facteur de 1 \u00e0 3 en m\u00e9tropole. On compte ainsi 2 interventions pour 10.000 habitants en Auvergne contre 6 pour 10 000 en r\u00e9gion Provence-Alpes-C\u00f4te d&rsquo;Azur et Languedoc Roussillon. Des taux qui ne refl\u00e8tent pas la fr\u00e9quence de l&rsquo;ob\u00e9sit\u00e9 comme en \u00ab\u00a0r\u00e9gion Paca qui a la pr\u00e9valence d&rsquo;ob\u00e9sit\u00e9 la plus faible\u00a0\u00bb, pointe le Pr Allemand. &#8230;<\/p>\n<p>PLOS MEDICINE\u00a0Published:\u00a0September 27, 2011<\/p>\n<p><strong><a href=\"http:\/\/www.plosmedicine.org\/article\/info%3Adoi%2F10.1371%2Fjournal.pmed.1001098\" target=\"_blank\">C<\/a><\/strong><a href=\"http:\/\/www.plosmedicine.org\/article\/info%3Adoi%2F10.1371%2Fjournal.pmed.1001098\" target=\"_blank\"><strong>ardiovascular risk with non-steroidal anti-inflammatoire drugs<\/strong>: systematic review of population-based controlled observational studies<\/a><\/p>\n<p>Randomised trials have highlighted the cardiovascular risks of non-steroidal anti-inflammatory drugs (NSAIDs) in high doses and sometimes atypical settings. Here, we provide estimates of the comparative risks with individual NSAIDs at typical doses in community settings.<\/p>\n<p>This review suggests that among widely used NSAIDs, naproxen and low-dose ibuprofen are least likely to increase cardiovascular risk. Diclofenac in doses available without prescription elevates risk. The data for etoricoxib were sparse, but in pair-wise comparisons this drug had a significantly higher RR than naproxen or ibuprofen. Indomethacin is an older, rather toxic drug, and the evidence on cardiovascular risk casts doubt on its continued clinical use.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>08\/05\/2013 En Belgique, le cas d&rsquo;un enfant atteint d&rsquo;une maladie rare suscite la pol\u00e9mique Jean-Pierre Stroobants Le Monde Un petit gar\u00e7on de 7 ans, Viktor Ameys, pourra continuer \u00e0 vivre gr\u00e2ce \u00e0 un m\u00e9dicament tr\u00e8s co\u00fbteux susceptible de soigner la &hellip; <a href=\"http:\/\/surmedicalisation.fr\/?page_id=109\">Continuer la lecture <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":7,"comment_status":"open","ping_status":"open","template":"","meta":[],"_links":{"self":[{"href":"http:\/\/surmedicalisation.fr\/index.php?rest_route=\/wp\/v2\/pages\/109"}],"collection":[{"href":"http:\/\/surmedicalisation.fr\/index.php?rest_route=\/wp\/v2\/pages"}],"about":[{"href":"http:\/\/surmedicalisation.fr\/index.php?rest_route=\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"http:\/\/surmedicalisation.fr\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"http:\/\/surmedicalisation.fr\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=109"}],"version-history":[{"count":19,"href":"http:\/\/surmedicalisation.fr\/index.php?rest_route=\/wp\/v2\/pages\/109\/revisions"}],"predecessor-version":[{"id":2538,"href":"http:\/\/surmedicalisation.fr\/index.php?rest_route=\/wp\/v2\/pages\/109\/revisions\/2538"}],"wp:attachment":[{"href":"http:\/\/surmedicalisation.fr\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=109"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}